An Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX464 in HIV-1 Seronegative and Seropositive Adults
Phase of Trial: Phase I/II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs ABX 464 (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors Abivax
- 15 Dec 2017 Results prented in an Abivax media release.
- 15 Dec 2017 According to an Abivax media release, data will be presented in an oral plenary session at the 8th International Workshop on HIV Persistence During Therapy.
- 12 Dec 2017 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.